doxazosin has been researched along with indoramin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondinell, WE; Hieble, JP; Ruffolo, RR | 1 |
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Pedretti, A; Testa, B; Villa, L; Vistoli, G | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Gagało, I; Szreder, Z | 1 |
| Andersson, KE; Ishizuka, O; Mattiasson, A; Steers, WD | 1 |
| Fernández Arjona, M; Fernández Borrell, A; Gómez Sancha, F; Mínguez Martínez, R; Peinado Ibarra, F; Pereira Sanz, I | 1 |
| Clifford, GM; Farmer, RD | 1 |
4 review(s) available for doxazosin and indoramin
| Article | Year |
|---|---|
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
Topics: Animals; Humans; Molecular Biology; Molecular Structure; Radioligand Assay; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1995 |
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2000 |
5 other study(ies) available for doxazosin and indoramin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
Topics: Chemical Phenomena; Chemistry, Physical; Ligands; Models, Molecular; Molecular Conformation; Monte Carlo Method; Quantitative Structure-Activity Relationship; Receptors, Adrenergic, alpha-1; Solvents | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
The effect of doxazosin, urapidil and indoramin pretreatment on fever produced by E. coli lipopolysaccharide in rabbits.
Topics: Adrenergic alpha-Antagonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature Regulation; Doxazosin; Escherichia coli; Female; Fever; Indoramin; Lipopolysaccharides; Male; Piperazines; Prazosin; Rabbits | 1991 |
Effects of spinal alpha 1-adrenoceptor antagonism on bladder activity induced by apomorphine in conscious rats with and without bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Dopamine Agonists; Doxazosin; Female; Hypertrophy; Indoramin; Injections, Intra-Arterial; Injections, Spinal; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Reference Values; Spinal Cord; Urinary Bladder; Urinary Bladder Neck Obstruction | 1997 |